The tumor-inhibitory αSMA-positive CAFs are driven by specific tumor-suppressive signaling pathways (Chen et al. 2021a, b, c; Lee et al. 2014; Shin et al. 2014; Tanaka et al. 2022), such as the SHH signaling pathway. Here, ACTA1 is linked to neoplasm.